Align Technology (NASDAQ:ALGN) shares are up in double digits today after the maker of medical devices delivered better-than-anticipated second-quarter numbers. Revenue rose 3.1% year-over-year to $1 billion, outperforming estimates by $9.2 million. EPS at $2.22 too comfortably landed past estimates by $0.18.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Strong momentum in Submitters and Utilization coupled with growth in Invisalign First led to a 10% year-over-year increase in Clear Aligner cases for teenagers. Further, Clear aligner volume rose by 5% sequentially to 604,400 cases.
Looking ahead, for the full-year 2023, the company sees top-line ranging between $3.970 billion and $3.990 billion. While the operating margin is expected to be 21%+., capital expenditures are envisaged at ~$200 million.
Further, revenue for the third quarter is expected between $990 million and $1,010 million pointing to a 12% year-over-year growth at the midpoint.
Overall, the Street has a $343.33 consensus price target on Align alongside a Moderate Buy consensus rating. After surging nearly 35% over the past year, Align shares are up a further 15.6% at the time of writing today.
Read full Disclosure